All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	4229	209860-87-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tafluprost tafluprost ophthalmic solution zioptan taflotan tapros	a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow Molecular weight: 452.54 Formula: C25H34F2O5 CLOGP: 4.26 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 75.99 ALOGS: -4.93 ROTB: 13 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1	22
kinase-selectivity-class	AXL,GRK2	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	1

Approvals:

Date	Agency	Company	Orphan
Feb. 10, 2012	FDA	OAK PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	219.94	32.78	57	1167	33741	90593482
Eye irritation	158.02	32.78	44	1180	33934	90593289
Eye pain	150.96	32.78	45	1179	44123	90583100
Eye pruritus	114.12	32.78	33	1191	28994	90598229
Intraocular pressure increased	66.09	32.78	16	1208	7077	90620146
Eye swelling	58.95	32.78	20	1204	29366	90597857
Vision blurred	44.41	32.78	24	1200	110269	90516954

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	81.32	48.61	21	422	15942	42604950
Eye irritation	63.01	48.61	16	427	11302	42609590

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	145.32	30.55	42	1362	39244	110548651
Eye pain	94.37	30.55	32	1372	50067	110537828
Eye irritation	77.52	30.55	25	1379	33427	110554468
Eye pruritus	61.92	30.55	21	1383	32754	110555141
Intraocular pressure increased	55.54	30.55	15	1389	10861	110577034
Atrioventricular block second degree	40.44	30.55	11	1393	8170	110579725
Vision blurred	36.93	30.55	22	1382	129000	110458895
Pemphigoid	34.75	30.55	12	1392	19695	110568200
Cardiovascular insufficiency	34.11	30.55	8	1396	3280	110584615

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EE05	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA CS	M0017805	Prostaglandins
FDA MoA	N0000000106	Prostaglandin Receptor Agonists
FDA PE	N0000009526	Increased Prostaglandin Activity
FDA EPC	N0000175454	Prostaglandin Analog
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:66900	prostaglandin receptor agonist

Related Drugs by ATC class:

S01EE Prostaglandin analogues 6 drugs

bimatoprostdorzolamidelatanoprostlatanoprostene bunodnetarsudiltravoprost

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.0015%	ZIOPTAN	THEA PHARMA	N202514	Feb. 10, 2012	RX	SOLUTION/DROPS	OPHTHALMIC	10864159	May 28, 2029	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
4031331	VUID
N0000184322	NUI
D06274	KEGG_DRUG
4031331	VANDF
C1451502	UMLSCUI
CHEBI:66899	CHEBI
CHEMBL1963683	ChEMBL_ID
DB08819	DRUGBANK_ID
C485333	MESH_SUPPLEMENTAL_RECORD_UI
7451	IUPHAR_LIGAND_ID
8374	INN_ID
1O6WQ6T7G3	UNII
9868491	PUBCHEM_CID
1244607	RXNORM
187543	MMSL
26696	MMSL
013244	NDDF
699181001	SNOMEDCT_US
704470009	SNOMEDCT_US
1O6WQ6T7G3	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6184	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	ANDA	24 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	17478-609	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA	25 sections
tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	42571-264	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	ANDA	23 sections
Tafluprost	HUMAN PRESCRIPTION DRUG LABEL	1	50742-339	SOLUTION/ DROPS	0.02 mg	OPHTHALMIC	ANDA	23 sections
Tafluprost Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	66993-429	SOLUTION/ DROPS	0.00 mg	OPHTHALMIC	NDA authorized generic	25 sections
ZIOPTAN	HUMAN PRESCRIPTION DRUG LABEL	1	82584-609	SOLUTION/ DROPS	0.02 mg	OPHTHALMIC	NDA	26 sections